TAILIEUCHUNG - Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012

After program outcomes are defined in general terms, the next step is to translate the statements into specific indicators that will be measured. For each outcome, the working group needs to identify one or more outcome indicators that could be measured to track progress toward the outcomes. Key criteria are the feasibility and cost of measurement. Outcome indicators should almost always begin with words such as “The number of . . .” or “The percent of . . .” Exhibit 8 illustrates the relationship between a program’s mission/objectives, outcomes, and outcome indicators. Although data sources and collection procedures are discussed in step 7, the final selection of the specific outcome. | Special Articles Surviving Sepsis Campaign International Guidelines for Management of Severe Sepsis and Septic Shock 2012 R. Phillip Dellinger MD1 Mitchell M. Levy MD2 Andrew Rhodes MB BS3 Djillali Annane MD4 Herwig Gerlach MD PhD5 Steven M. Opal MD6 Jonathan E. Sevransky MD7 Charles L. Sprung MD8 Ivor S. Douglas MD9 Roman Jaeschke MD10 Tiffany M. Osborn MD MPH11 Mark E. Nunnally MD12 Sean R. Townsend MD13 Konrad Reinhart MD14 Ruth M. Kleinpell PhD RN-CS15 Derek C. Angus MD MPH16 Clifford S. Deutschman MD MS17 Flavia R. Machado MD PhD18 Gordon D. Rubenfeld MD19 Steven A. Webb MB BS PhD20 Richard J. Beale MB BS21 Jean-Louis Vincent MD PhD22 Rui Moreno MD PhD23 and the Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup Objective To provide an update to the Surviving Sepsis Campaign Guidelines for Management of Severe Sepsis and Septic Shock last published in 2008. Design A consensus committee of 68 international experts representing 30 international organizations was convened. Nominal groups were assembled at key international meetings for those committee members attending the conference . A formal conflict of interest policy was developed at the onset of the process and enforced throughout. The entire guidelines process was conducted independent of any industry funding. A stand-alone meeting was held for all subgroup heads co- and vice-chairs and selected individuals. Teleconferences and electronic-based discussion among subgroups and among the entire committee served as an integral part of the development. 1 Cooper University Hospital Camden New Jersey. 2 Warren Alpert Medical School of Brown University Providence Rhode Island. 3 St. George s Hospital London United Kingdom. 4 Hôpital Raymond Poincaré Garches France. 5 Vivantes-Klinikum Neukolln Berlin Germany. 6 Memorial Hospital of Rhode Island Pawtucket Rhode Island. 7 Emory University Hospital Atlanta Georgia. 8 Hadassah Hebrew University Medical Center Jerusalem Israel. 9 Denver .

• Y khoa - Dược
• Drug treatment
• short course
• treatment failure
• health and nutrition
• education
• gen
• Tạp chí khoa học
• Tạp chí y dược
• Y dược quân sự
• Drug resistance
• First line antiretroviral treatment failure
• Genetic mutation for drug resistance
• Bài viết nghiên cứu khoa học
• Drug treatment of dyslipidemia
• Military Hospital 105
• Patients' LDL C
• renal drug treatment of kidney disease
• kidney treatment
• kidney disease prevention
• Approved Drug Products
• Approved Drug
• BMC Cancer
• Oncology clinical trial drug interaction
• Increased risk
• Drug drug interactions
• Increase treatment toxicity
• Descriptive statistics
• BMC Genomics
• Drug resistant tuberculosis
• Genetic changes
• Pre extensively drug resistant
• Cardiovascular pharmacotherapeutics
• Complementarymedicine for preventing
• Treatingcardiovascular disease
• Cardiovascular drug–drug interactions
• Drug treatment of peripheral vascular disorders
• Cardiovascular drugs in development
• Pediatric cardiovascular pharmacology
• Adolescent psychiatry
• Mental health
• Adverse drug events
• Therapeutic drug monitoring
• Drug naïve population
• Child psychiatry
• aids
• hiv
• china
• guangxi
• province
• confinement
• mandatory
• cycle
• drug
• dependency
• treatment
• BMC Pulmonary Medicine
• Multi drug resistant tuberculosis
• Standard short course chemotherapy
• Acquired drug resistant tuberculosis emergence
• Multivariate logistic regression;
• Methods employed
• Diagnosis of pulmonary
• Clinical diagnosis
• Neonatal abstinence syndrome
• Disorder treatment access
• Public health
• Outpatient treatment programs
• Drug withdrawal syndrome
• new drug regimens
• Expanded discussion
• Drug information
• bibliographies
• medicine
• complementary therapies
• antiphospholipid syndrome
• lipid disorders
• Polysaccharides for Colon
• Targeted Drug Delivery
• Improved Drug
• Release Specificity
• Therapeutic Benefits
• Factors in Pathogenesis
• Preparation of cellulose coated hydrogels
• Controlled drug release
• Cellulose coated microparticles
• Cross linkage treatment
• Harmful and sophisticated
• ABC of epilepsy
• Classifying the condition
• Making the diagnosis
• Clinical examination
• Managing the drug treatment
• Repeated seizures
• Non drug treatments including epilepsy surgery
• Breast cancer
• Computational framework
• Drug repurposing
• Dynamic gene expression
• Entering clinical trials
• Hepatocellular carcinoma
• Conventional transarterial chemoembolization
• Drug eluting bead transarterial chemoembolization
• According to mRECIST
• Palliative treatments
• BMC Pediatrics
• Introduction of antiretroviral therapy
• Treatment of paediatric HIV infection
• Drug intake logistics
• Therapeutic failure
• BMC Pharmacology and Toxicology
• Type 2 diabetes mellitus
• Peripheral edema
• Weight gain
• Antihypertensive drug therapy
• Prospective study
• Blood pressure
• Calcium channel blockers
• Drug screen
• Cell fate
• Extracellular matrix
• RAF inhibitor
• MAPK pathway
• BMC Molecular and Cell Biology
• Epidermal growth factor receptor
• EGFR signaling
• Signaling crosstalk
• Geometric properties
• Tuberculosis